AEON Biopharma, Inc. (AEON) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-30

Key Insights

AEON Biopharma, Inc. reported its financial results for the year ended December 31, 2025, indicating the company's performance during that period.
The filing does not provide any additional details about the company's financial condition, operations, or material events that occurred during the reported timeframe.
Without more information in the 8-K filing, it is difficult to assess the significance or implications of the reported financial results for AEON Biopharma's investors.

Want the newest filings?

This analysis covers the filing from 2026-03-30. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-09

AEON Biopharma has appointed John Bencich as its new Chief Financial Officer, strengthening the company's executive leadership team as it advances key regulatory and financing milestones.
Bencich brings over 25 years of financial and leadership experience in the biotechnology and life sciences sectors, which could help AEON execute on its strategic initiatives.
The employment agreement provides Bencich with a competitive compensation package, including a base salary, annual bonus opportunity, and severance benefits in the event of termination without cause or resignation for good reason, especially in the context of a change in control.

Filed: 2026-01-21

AEON Biopharma has entered into an exchange agreement with Daewoong Pharmaceutical to satisfy its outstanding senior secured convertible notes, which will result in the issuance of new common stock, warrants, and a new convertible note.
The company held a special meeting of stockholders on January 21, 2026, where shareholders approved the PIPE financing proposal, the exchange proposal with Daewoong, and the amended 2023 Incentive Award Plan.
Following the exchange and stockholder approvals, AEON Biopharma has 24,024,282 shares of common stock outstanding as of January 21, 2026.

Filed: 2026-01-12

AEON Biopharma is an emerging growth company, which means it may have more flexibility in financial reporting and less stringent disclosure requirements.
The company has filed an 8-K to disclose the release of a corporate presentation on its investor relations website, which may provide additional insights into its business and financial performance.
As an 8-K filing, this event is likely to be of moderate significance to investors, as it represents the disclosure of potentially material information about the company.

Other reports for AEON Biopharma, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.